NCT01119352

AZD7687 Multiple Ascending Dose Study

A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Multiple Ascending Doses in Overweight to Obese But Otherwise Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects

Conditions

• Overweight
• Obese

Interventions

Type	Name	Description
DRUG	AZD7687	Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
DRUG	Placebo	Oral suspension, once daily. Totally 8 doses

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-05-07
• Last updated: 2012-01-19

Locations

1 site across 1 country: United Kingdom